Back
Eli Lilly and Co (LLY)
PharmaceuticalsLLY · NEW YORK STOCK EXCHANGE, INC. · USD
New to investing? How to read this page →$1188.72
+2.70%Weekly undervalued picks
Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for research and education only. Not financial advice.
Key metrics
EPS
$22.95
ROE
107.5%
Gross margin
82.8%
Debt/Equity
1.39x
Revenue growth
55.5%
Eli Lilly and Co — company intelligence
Earnings surprises
Q2 2026$8.38 vs $6.07 est+38.1%
Q1 2026$8.55 vs $6.73 est+27.0%
Q4 2025$7.54 vs $6.74 est+11.9%
Q3 2025$7.02 vs $5.75 est+22.0%
Analyst consensus · 38 analysts
30 Buy7 Hold1 Sell
Updated Oct 7, 2026
Insider activity · 90 days
12 buys4 sellsnet -13,828 shares
Fyrwald J ErikBuy 9 · Sep 21, 2026
Sulzberger GabrielleBuy 4 · Sep 21, 2026
LUCIANO JUAN RBuy 14 · Sep 21, 2026
Recent SEC filings
4 — Insider transaction reportSep 22, 2026
4 — Insider transaction reportSep 22, 2026
4 — Insider transaction reportSep 22, 2026
Latest news
FDA approves Lilly's Olumiant (baricitinib) for pediatric patients 12 years of age and older with severe alopecia areata — Yahoo · 2w ago
Sector Update: Healthcare Stocks Edge Higher in Afternoon Trading — Yahoo · 2w ago
This week in charts: Novo’s rise and fall and AI biotechs’ big haul — Yahoo · 2w ago
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
Weekly undervalued picks
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.